Pickett C A, Gutierrez-Hartmann A
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.
Mol Cell Biol. 1995 Dec;15(12):6777-84. doi: 10.1128/MCB.15.12.6777.
We have previously demonstrated that epidermal growth factor (EGF) produces activation of the rat prolactin (rPRL) promoter in GH4 neuroendocrine cells via a Ras-independent mechanism. This Ras independence of the EGF response appears to be cell rather than promoter specific. Oncogenic Ras also produces activation of the rPRL promoter when transfected into GH4 cells and requires the sequential activation of Raf kinase, mitogen-activated protein (MAP) kinase, and c-Ets-1/GHF-1 to mediate this response. In these studies, we have investigated the interaction between EGF and Ras in stimulating rPRL promoter activity and the role of Raf and MAP kinases in mediating the EGF response. We have also examined the role of several transcription factors and used various promoter mutants of the rPRL gene in order to better define the trans- and cis-acting components of the EGF response. EGF treatment of GH4 cells inhibits activation of the rPRL promoter produced by transfection of V12Ras from 24- to 4-fold in an EGF dose-dependent manner. This antagonistic effect of EGF and Ras is mutual in that transfection of V12Ras also blocks EGF-induced activation of the rPRL promoter in a Ras dose-dependent manner, from 5.5- to 1.6-fold. Transfection of a plasmid encoding the dominant-negative Raf C4 blocks Ras-induced activation by 66% but fails to inhibit EGF-mediated activation of the rPRL promoter. Similarly, transfection of a construct encoding an inhibitory form of MAP kinase decreases the Ras response by 50% but does not inhibit the EGF response. Previous studies have demonstrated that c-Ets-1 is necessary and that GHF-1 acts synergistically with c-Ets-1 in the Ras response of the rPRL promoter. In contrast, overexpression of neither c-Ets-1 nor GHF-1 enhanced EGF-mediated activation of the rPRL promoter, and dominant-negative forms of these transcription factors failed to inhibit the EGF response. Using 5' deletion and site-specific mutations, we have mapped the EGF response to two regions on the proximal rPRL promoter. One region maps between -255 and -212, near the Ras response element, and a second maps between -125 and -54. The latter region appears to involve footprint 2, a previously identified repressor site on the rPRL promoter. Neither footprint 1 nor 3, known GHF-1 binding sites, appears to be crucial to RGF-mediated rPRL promoter activation. The results of these studies indicate that in GH4 neuroendocrine cells, rPRL gene regulation by EGF is mediated by a signal transduction pathway that is separate and antagonistic to the Ras pathway. Hence, the functional role of the Ras/Raf/MAP kinase pathway in mediating transcriptional responses to EGF and other receptor tyrosine kinase may differ in highly specialized cell types.
我们之前已经证明,表皮生长因子(EGF)通过一种不依赖Ras的机制,在GH4神经内分泌细胞中激活大鼠催乳素(rPRL)启动子。EGF反应的这种Ras非依赖性似乎是细胞特异性而非启动子特异性的。致癌性Ras转染到GH4细胞中时也会激活rPRL启动子,并且需要Raf激酶、丝裂原活化蛋白(MAP)激酶和c-Ets-1/GHF-1的顺序激活来介导这种反应。在这些研究中,我们研究了EGF和Ras在刺激rPRL启动子活性方面的相互作用,以及Raf和MAP激酶在介导EGF反应中的作用。我们还研究了几种转录因子的作用,并使用了rPRL基因的各种启动子突变体,以便更好地确定EGF反应的反式和顺式作用成分。用EGF处理GH4细胞会以EGF剂量依赖性方式将V12Ras转染产生的rPRL启动子激活从24倍抑制到4倍。EGF和Ras的这种拮抗作用是相互的,因为V12Ras转染也会以Ras剂量依赖性方式将EGF诱导的rPRL启动子激活从5.5倍阻断到1.6倍。转染编码显性负性Raf C4的质粒可将Ras诱导的激活阻断66%,但不能抑制EGF介导的rPRL启动子激活。同样,转染编码抑制形式MAP激酶的构建体可使Ras反应降低50%,但不抑制EGF反应。先前的研究表明,c-Ets-1是必需的,并且GHF-1在rPRL启动子的Ras反应中与c-Ets-1协同作用。相比之下,c-Ets-1和GHF-1的过表达均未增强EGF介导的rPRL启动子激活,并且这些转录因子的显性负性形式也未能抑制EGF反应。通过5'缺失和位点特异性突变,我们将EGF反应定位到近端rPRL启动子上的两个区域。一个区域位于-255至-212之间,靠近Ras反应元件,另一个区域位于-125至-54之间。后一个区域似乎涉及足迹2,这是rPRL启动子上先前鉴定的一个抑制位点。已知的GHF-1结合位点足迹1和足迹3似乎对RGF介导的rPRL启动子激活都不是至关重要的。这些研究结果表明,在GH4神经内分泌细胞中,EGF对rPRL基因的调控是由一条与Ras途径分开且拮抗的信号转导途径介导的。因此,Ras/Raf/MAP激酶途径在介导对EGF和其他受体酪氨酸激酶的转录反应中的功能作用在高度特化的细胞类型中可能有所不同。